By admin 
The appointment of John Polson, Chairman and Managing Partner of the international labor and employment law firm Fisher Phillips, to the CureSearch for Children’s Cancer Board of Directors marks a significant strategic expansion for the non-profit organization. This move comes at a pivotal time for CureSearch, as the institution continues to outperform national benchmarks in moving pediatric cancer treatments from the laboratory to clinical application. Polson, a legal veteran with more than three decades of experience in high-level corporate governance and strategic leadership, is expected to provide the oversight necessary to scale the organization’s reach and impact. His transition into this formal leadership role follows a long-standing philanthropic relationship between his firm and the foundation, highlighting a deep-seated commitment to the eradication of childhood cancer through innovative research and community engagement.
Strategic Leadership and Legal Expertise
John Polson’s professional background brings a unique set of skills to the CureSearch board. As the head of Fisher Phillips, he manages the operations of 41 offices worldwide, overseeing a workforce of hundreds of attorneys and support staff. Under his tenure, the firm has not only expanded its geographical footprint but has also maintained a reputation for excellence, consistently appearing in prestigious rankings such as The Best Lawyers in America and The Legal 500. This experience in managing a complex, multi-national organization is particularly relevant for CureSearch, which operates in the highly regulated and intricate landscape of medical research funding and pharmaceutical development.
In the non-profit sector, the role of a board member extends beyond simple oversight; it involves strategic vision and the ability to navigate the intersection of private industry, government regulation, and academic research. Polson’s expertise in labor and employment law provides a foundation for organizational stability, while his experience in strategic planning is expected to assist CureSearch in optimizing its internal processes and external partnerships. The addition of a high-profile legal leader suggests a move toward more robust corporate governance as the organization seeks to attract larger institutional donors and navigate the complexities of clinical trial pipelines.
A History of Philanthropic Commitment: The FP Cares Initiative
The relationship between John Polson and CureSearch is not a new development but rather the culmination of years of active support. Through Fisher Phillips’ philanthropic arm, known as FP Cares, Polson has spearheaded initiatives that have directly contributed to the advancement of pediatric oncology research. One of the most notable achievements under his leadership was the firm’s successful fundraising effort that generated $200,000 for CureSearch’s research programs.
Beyond financial contributions, Polson encouraged a culture of empathy and direct action within his firm. Fisher Phillips was a primary participant in the “Notes of Hope” campaign, a grassroots initiative where firm employees across the globe authored thousands of personalized, handwritten letters to children undergoing intensive cancer treatments. These letters served as a morale booster for patients and their families, addressing the emotional and psychological toll that a cancer diagnosis takes on a household.
In recognition of these sustained efforts, CureSearch previously honored Fisher Phillips with the “Champion for Cures” award. This distinction is reserved for corporate partners who demonstrate an exceptional level of dedication to the organization’s mission, moving beyond transactional donations to foster a deep, mission-aligned partnership. Polson’s appointment to the board is seen as a natural progression of this alliance, transitioning him from a lead supporter to a key architect of the organization’s future.
Analyzing the State of Pediatric Cancer Research
The urgency of Polson’s appointment is underscored by the current state of pediatric oncology in the United States and globally. While cancer remains the leading cause of death by disease for children, the field has historically been underfunded compared to adult oncology. According to data from the National Cancer Institute (NCI), only a small fraction of federal cancer research funding is specifically allocated to pediatric-only cancers. This disparity creates what researchers often call the “valley of death,” where promising laboratory discoveries fail to reach the clinical trial stage due to a lack of financial backing and institutional support.
CureSearch has positioned itself as a disruptor in this space. The organization focuses on a “bench-to-bedside” model, prioritizing projects that have a high probability of clinical success. The data supporting CureSearch’s approach is compelling: currently, 60% of CureSearch-funded preclinical projects advance to clinical trials. When contrasted with the national average for cancer trials—which hovers around 8%—it becomes clear that CureSearch’s vetting and funding process is exceptionally efficient. This high success rate is a primary reason why the organization seeks board members like Polson, who understand how to maintain high performance and accountability in large-scale operations.
Official Responses and Organizational Vision
The leadership at CureSearch has expressed high expectations for the impact Polson will have on the board. Kay Koehler, President and CEO of CureSearch for Children’s Cancer, emphasized that Polson’s ability to build relationships and his proven track record of social impact were decisive factors in his recruitment.
“We are thrilled to welcome John Polson to the CureSearch Board of Directors,” Koehler stated. “John’s proven leadership, deep commitment to social impact, and ability to build strong relationships will be invaluable as we continue our work to bring life-saving treatments to children with cancer. His experience and vision will help us take our mission to the next level, and we are honored to have him by our side in the fight to end childhood cancer.”
For his part, Polson has voiced a personal connection to the cause, stating that the fight against childhood cancer is one that is “very close” to his heart. His goal on the board will be to leverage his professional network and strategic acumen to drive the organization’s critical work in advancing research and providing hope to families. He joins a board comprised of a diverse group of stakeholders, including pediatric oncologists, business executives, and patient advocates, all of whom are tasked with ensuring that every child diagnosed with cancer has access to the latest medical advancements.
The Chronology of Impact: A Timeline of Partnership
The path to Polson’s board appointment is defined by several key milestones that illustrate the deepening tie between the legal industry and medical philanthropy:
- Launch of FP Cares: Fisher Phillips establishes its charitable arm to formalize its commitment to community service and social responsibility.
- Initial Partnership with CureSearch: The firm identifies pediatric cancer as a primary focus area, aligning its resources with CureSearch’s mission-driven research.
- The $200,000 Milestone: Through firm-wide participation and Polson’s advocacy, FP Cares hits a significant fundraising target, providing a substantial boost to preclinical research grants.
- Notes of Hope Campaign: Employees across 41 offices contribute thousands of letters, highlighting the firm’s internal culture of volunteerism.
- Champion for Cures Award: CureSearch officially recognizes Fisher Phillips for its outstanding corporate citizenship.
- Board Appointment (Present): John Polson is officially named to the Board of Directors, transitioning to a role of strategic governance.
Broader Implications for Pediatric Oncology
The inclusion of a global law firm chairman on the board of a medical research non-profit reflects a broader trend in the philanthropic sector: the professionalization of advocacy. As the search for cancer cures moves toward increasingly complex areas like immunotherapy, genomic sequencing, and personalized medicine, the organizations funding this research must operate with the precision of a venture capital firm and the ethical rigor of a healthcare provider.
Polson’s presence is likely to enhance CureSearch’s ability to navigate the intellectual property (IP) challenges associated with new drug development. When a non-profit funds a breakthrough, ensuring that the resulting treatment remains accessible and affordable for families requires sophisticated legal and strategic planning. Furthermore, as CureSearch looks to expand its international reach, Polson’s experience in managing global operations will be a critical asset.
The 60% advancement rate of CureSearch projects suggests that the organization has found a successful formula for identifying viable treatments. However, moving from 60% to even higher levels of success—and ensuring those clinical trials result in FDA-approved therapies—requires an influx of capital and high-level corporate partnerships. Polson is uniquely positioned to act as a bridge between the corporate world and the medical research community, potentially opening new avenues for corporate social responsibility (CSR) initiatives that go beyond simple donations.
Conclusion: A New Chapter in the Fight Against Childhood Cancer
As John Polson begins his tenure on the CureSearch Board of Directors, the organization is well-positioned to continue its trajectory of high-impact research. The synergy between Polson’s legal leadership and CureSearch’s scientific rigor creates a robust platform for future growth. In a field where the stakes are life and death for thousands of children annually, the integration of world-class business strategy into the research pipeline is more than just an administrative update—it is a vital component of the modern effort to transform the landscape of pediatric medicine.
The focus now shifts to the upcoming fiscal year, where Polson and his fellow board members will be tasked with overseeing new grant cycles and expanding the “Notes of Hope” initiative to reach more hospitals nationwide. With a 60% success rate as their foundation, the goal remains clear: to ensure that no child’s life is cut short by a lack of research or a lack of hope. Through this appointment, CureSearch reinforces its commitment to bringing the best minds from every sector—legal, corporate, and medical—to the front lines of the battle against childhood cancer.
